Name: Oxford Cannabinoid's breakthrough oral immunotherapy: “The initial data demonstrates excellent potential”
Uploaded: 2023-07-17T13:35:36.689593+00:00
Duration: 340 s
Channel: Vox Markets

Vox Markets

In this video, Vox Markets talks to Clarissa Sowemimo-Coker, CEO of Oxford Cannabinoid, a biotech company focused on developing prescription medications from cannabinoids, taking Vox through the company's mission to address unmet patient needs, particularly within the US multi-billion dollar pain market. They announce their expansion into oncology and the potential of a first-in-class oral immunotherapy for solid tumors.

<p>In this video, Vox Markets talks to Clarissa Sowemimo-Coker, CEO of Oxford Cannabinoid, a biotech company focused on developing prescription medications from cannabinoids, taking Vox through the company's mission to address unmet patient needs, particularly within the US multi-billion dollar pain market. They announce their expansion into oncology and the potential of a first-in-class oral immunotherapy for solid tumors.</p>

Introducing Oxford Cannabinoid, its focus on the pain market and current pipeline

Expansion into oncology

Plans for progression of its immuno-oncology treatment toward clinical trials

How its immuno-oncology treatment is set apart from market competitors

Other projects in the pipeline

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/006/039/006039/video_egYE473.mp4